Hi All,
Perhaps they have at last found a "test" that can indicate if a patient will respond to treatment with Vidaza (azacitidine or AZA) before the treatment is started.
"We have identified a DNA methylation signature that correlates with Overall Survival in the unpurified pre-treatment BoneMarrow aspirate samples of AZA-treated higher-risk MDS patients. We have also demonstrated that DNA methylation of WT1 loci alone was predictive of Overall Survival. As these markers could be used to make therapeutic choices for patients with MDS, their predictive values warrant further validation in a larger independent data set."
http://ash.confex.com/ash/2011/webpr...aper41576.html
Kind regards
Birgitta-A